RBC Capital Sticks to Their Buy Rating for Tenet Healthcare (THC)

RBC Capital analyst Ben Hendrix reiterated a Buy rating on Tenet Healthcare yesterday and set a price target of $236.00. The company’s shares closed yesterday at $177.12.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Hendrix is a 4-star analyst with an average return of 5.7% and a 51.65% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Community Health, and Brookdale Senior Living.

Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $257.69, which is a 45.49% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $252.00 price target.

Based on Tenet Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.53 billion and a net profit of $371 million. In comparison, last year the company earned a revenue of $5.07 billion and had a net profit of $318 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in March 2026, Paola M Arbour, the EVP & CIO of THC sold 6,500.00 shares for a total of $1,549,795.00.